CD274 and metastatic melanoma: Additionally, a clinical phase I/II trial shows that Nivolumab combined with IO102/IO103 (an immune regulatory vaccine targeting IDO and PD-L1) achieves a high ORR of 80% in metastatic melanoma patients, with 43% achieving complete remission, this combination significantly decreases the tumor burden and extends PFS to 26 months [449].